COVID-19: Corporate Update 03/23/2020
Donation of hydroxychloroquine to hospitals to combat COVID-19
JAMP Pharma Group announces that it is donating one million doses of hydroxychloroquine to Canadian hospitals, a drug that is normally used to treat malaria and rheumatoid arthritis and which could potentially be useful in treating hospitalized patients infected with the COVID-19 virus.
Considerable efforts is being made to find effective treatments for COVID-19 and, while treatments are still being studied, it appears that preliminary results(1) on hydroxychloroquine in patients who’ve contracted the virus have caught the attention of scientists, doctors and researchers.
“JAMP Pharma Group is pleased to contribute to the collective efforts of governments and health partners in the attempt to contain the effects of COVID-19. Solidarity and mutual aid are precious assets in times of crisis. We have a duty to do everything in our power to help Canadians through this,” said Louis Pilon, President/CEO of JAMP Pharma Group.
The company is already in touch with many healthcare stakeholders who are managing this crisis to offer its collaboration.
The purpose of this generous donation to Canadian hospitals is twofold: JAMP Pharma Group wants to maximize the availability of the drug to the country’s health establishments for hospitalized patients who have contracted COVID-19, but also wants to avoid a shortage of the medication for persons using or needing hydroxychloroquine to treat the diseases for which the medication was approved by Health Canada.
COVID-19: Corporate Update 03/17/2020
Dear Customers and Patients,
We would like to provide an update on our action plan to manage the COVID-19 crisis.
Based on our detailed evaluation combined with our strategic efforts to prepare for operational disruptions, we do not anticipate any short term inventory or supply issues. We will continue to monitor the situation very closely and remain in continuous communication with you.
We appreciate all Canadian health care workers for their support and courage during this challenging period. We are committed to doing our very best to support all partners and frontline health care providers.
Below are some of the key measures we have implemented:
- We have created a crisis management team to ensure our operations will continue to run smoothly and clear prompt information us gathered and shared appropriately
- We have created essential services teams to ensure patients will continue to have uninterrupted access to their JAMP Pharma group medications and services
- We have taken significant measures to promote social distancing and have required all non-essential employees to work remotely to protect their health and the integrity of our operations
- We have instructed our outside field team to temporarily refrain from visiting pharmacies and medical clinics to eliminate the risk of infection to our employees or our pharmacy partners. Our representatives remain available to you via phone or email around the clock
Please do not hesitate to contact us if we can be of any help to you during this challenging period.
The JAMP Pharma Group communications team
Five biosimilars soon to be marketed in Canada!
We are very proud to announce the signature of an exclusive partenership agreement with Alvotech, a world-class biopharmaceutical company base in Reykjavik, Iceland, to soon market five biosimilar medecines for Canadian patients.
This historic agreement allows us to reaffirm our mission to improve access to affordable medicines for Canadian patients and to position ourselves as a major player in this market.
JAMP Pharma is a private Canadian company located in Boucherville, 20 minutes from Montreal. It is one of the leading generic players in the pharmaceutical industry in Canada, with more than 240 molecules in its portfolio.
JAMP Pharma has experienced phenomenal growth over the past 10 years and also owns natural health products Wampole, Laboratoire Suisse, Cosmetic Import and prescription products from Orimed Pharma.